Mechanism-based PK/PD model for the lymphocytopenia induced by endogenous and exogenous corticosteroids

被引:0
|
作者
Meibohm, B
Derendorf, H
Möllmann, H
Fröhlich, P
Tromm, A
Wagner, M
Homrighausen, S
Krieg, M
Hochhaus, G [1 ]
机构
[1] Univ Florida, Coll Pharm, Dept Pharmaceut, Gainesville, FL 32610 USA
[2] Ruhr Univ Bochum, Med Clin Bergmannsheil, Bochum, Germany
[3] Univ Tennessee, Coll Pharm, Dept Basic Pharmaceut Sci, Memphis, TN USA
[4] UFRGS, Fac Farm, Porto Alegre, RS, Brazil
关键词
pharmacokinetics; pharmacodynamics; corticosteroids; lymphocytes; modeling;
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: Lymphocytopenia is a sensitive surrogate marker for the immunological effects of corticosteroids. This pharmacokinetic/pharmacodynamic (PK/PD) study investigated whether the circadian variation of blood lymphocytes observed after placebo is secondary to the circadian rhythm of endogenous cortisol, and developed based on this relationship an improved PK/PD model for a more sensitive description of the effect of low-dose corticosteroid therapy on blood lymphocytes considering the net activity of the exogenous corticosteroid budesonide and endogenous cortisol. Methods: In an open, parallel study design, 3 mg oral budesonide or placebo were given at 8.00 a.m., 4.00 p.m. and midnight to two groups of 12 volunteers. Lymphocyte counts and serum concentrations of budesonide and cortisol were monitored for 24 hours. A mechanism-based PK/PD model which considered the non-linear protein binding of cortisol and the budesonide-induced cortisol suppression was employed to relate changes in blood lymphocytes to free cortisol levels after placebo and to the net activity of free budesonide and free endogenous cortisol after active treatment. Results: The circadian rhythm of blood lymphocytes observed after placebo could inversely be related to the circadian rhythm of serum cortisol. After budesonide administration, lymphocyte counts could accurately be linked to the net activity of budesonide and endogenous cortisol. The resulting EC50 Values for the effect of budesonide on cortisol, budesonide on lymphocytes and cortisol on lymphocytes were 0.063 +/- 0.034, 0.22 +/- 0.13 and 26.3 +/- 15.0 ng/ml (placebo group 15.4 +/- 3.4 ng/ml), respectively Conclusions: The presented mechanism-based PK/PD model suggests that blood lymphocytes are under physiological control of cortisol. It further indicates that endogenous and exogenous corticosteroids and their pharmacological interaction need to be considered for modeling the effects of low doses of exogenous corticosteroids on the immune system.
引用
收藏
页码:367 / 376
页数:10
相关论文
共 50 条
  • [1] Physiologically based PK/PD-model for the interaction between endogenous and exogenous corticosteroids and lymphocytes.
    Meibohm, B
    Derendorf, H
    Möllmann, H
    Wagner, M
    Fröehlich, P
    Hochhaus, G
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 201 - 201
  • [2] A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
    Ait-Oudhia, Sihem
    Zhang, Weiyan
    Mager, Donald E.
    AAPS JOURNAL, 2017, 19 (05): : 1436 - 1448
  • [3] A UNIFIED MECHANISM-BASED PK/PD MODEL FOR ANTIBODY DRUG CONJUGATE INDUCED HEMATOTOXICITY.
    Ait-Oudhia, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2017, 101 (S1) : S54 - S54
  • [4] A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates
    Sihem Ait-Oudhia
    Weiyan Zhang
    Donald E. Mager
    The AAPS Journal, 2017, 19 : 1436 - 1448
  • [5] Mechanism-based PK-PD model for Brain Dopamine Responses by Methylphenidate in Rats
    Shimizu, Ryosuke
    Horiguchi, Naotaka
    Yano, Koji
    Sakuramoto, Masashi
    Kanegawa, Naoki
    Shinohara, Shunji
    Ohnishi, Shuichi
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S106 - S106
  • [6] A mechanism-based pharmacokinetic/pharmacodynamic (PK/PD) model for omalizumab (rhuMAb-E25).
    Sun, YN
    Marian, M
    Schoenhoff, M
    Sinclair, D
    Fick, R
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2001, 69 (02) : P87 - P87
  • [7] A mechanism-based PK/PD model for the preclinical prediction of QT interval prolongation by dofetilide in man
    Jonker, DM
    Leishman, D
    Willis, R
    Milligan, PA
    Jonsson, EN
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 23 : S69 - S69
  • [8] A New Mechanism-based PK/PD Model for Antimicrobial Combinations of Colistin and Doripenem against Pseudomonas aeruginosa
    Ly, Neang S.
    Tsuji, Brian T.
    Rao, Gauri G.
    Kelchlin, Pamela A.
    Holden, Patricia N.
    Forrest, Alan
    Bergen, Phillip J.
    Nation, Roger L.
    Li, Jian
    Bulitta, Jurgen B.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2013, 40 : S116 - S117
  • [9] Exploration of differences between mechanism-based PK/PD and systems pharmacology models
    Demin, Oleg
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2016, 43 : S73 - S73
  • [10] The Pharmacokinetics/Pharmacodynamics of Resveratrol and Mechanism-based PK-PD Modeling Research
    Chen, Hui
    Liu, Xinxia
    Wan, Heng
    Zeng, Can
    FASEB JOURNAL, 2014, 28 (01):